Skip to main content
Fig. 1 | Clinical Epigenetics

Fig. 1

From: Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax

Fig. 1

miR-182 expression is lower in B-ALL cells than in NCs because of miR-182 promoter hypermethylation. A Relative miR-182 levels were measured in 38 untreated B-ALL cells and 14 NCs. B Shown are positive MSP frequencies at CpG island 3 of the miR-182 promoter in 5 ALL cell lines, 18 B-ALL samples, and 17 NCs. C and D Analysis of MSP and UMSP at the miR-182 promoter in 5 ALL cell lines, 18 B-ALL samples, and 17 NCs. The Bands in the ‘MSP’ and ‘UMSP’ lanes are PCR products amplified with methylation-specific and unmethylation-specific primers, respectively. NA: NALM-6; RS: RS4;11; Jur: Jurkat; M-4: MOLT-4. E Bisulfite genomic sequencing was used to assess the methylation status of CpG island 3 in two NC samples, two B-ALL samples, NALM-6, and Jurkat cell lines. Five colonies were shown for each sample. Each row of the circle represents the sequence of an individual clone. The black and empty circles represent methylated and unmethylated CpG dinucleotides, respectively (Left). Shown is the statistical analysis of the percentage of methylation (Right). F and G A MethylTarget™ assay was performed to analyze the percentage of DNA methylation at CpG islands 3 and 1 in 14 NCs, 19 B-ALL samples, and 5 ALL cell lines, including NALM-6, REH, RS4;11, Jurkat, and MOLT-4 cells. H A MethylTarget™ assay was performed to analyze the different DNA methylation at CpG islands 2 in 14 NCs and 19 B-ALL samples. I The percentage of DNA methylation at CpG islands 3, 1, and 2 was analyzed in 19 B-ALL samples. *P < 0.05; **P < 0.01; ***P < 0.001. NS: Not significant

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us